Composite Indicator
Trend Spotter (TM) Buy

Short Term Indicators
7 Day Average Directional Indicator Buy
10 - 8 Day Moving Average Hilo Channel Buy
20 Day Moving Average vs Price Buy
20 - 50 Day MACD Oscillator Buy
20 Day Bollinger Bands Buy

Short Term Indicators Average: 100% - Buy
20-Day Average Volume - 1078520

Medium Term Indicators
40 Day Commodity Channel Index Buy
50 Day Moving Average vs Price Buy
20 - 100 Day MACD Oscillator Sell
50 Day Parabolic Time/Price Buy

Medium Term Indicators Average: 50% - Buy
50-Day Average Volume - 627524

Long Term Indicators
60 Day Commodity Channel Index Buy
100 Day Moving Average vs Price Buy
50 - 100 Day MACD Oscillator Sell

Long Term Indicators Average: 33% - Buy
100-Day Average Volume - 424899

Overall Average: 72% - Buy

NEW YORK/TOKYO, Dec 24 (Reuters) - Japanese drugmaker Sankyo Co (Tokyo:4501.T - News) on Tuesday agreed to pay Cygnus Inc (OTC BB:CYGN.OB - News), a maker of glucose monitoring services, $30 million to resolve a dispute involving the U.S. company's "Biographer" device for diabetes patients.

Under the agreement reached by Cygnus and the Japanese firm's fully owned U.S. subsidiary, Sankyo Pharma Inc, Sankyo also will transfer title to all its GlucoWatch G2 Biographer products to Cygnus, the companies said in a joint statement.

The agreement, which includes about 20,000 G2 Biographer products and 1 million AutoSensors, is effective immediately, they added.

Cygnus, based in Redwood City, California, filed a lawsuit in October seeking $450 million in damages for breach of contract against Sankyo, Japan's second-largest drugmaker, and Sankyo Pharma Inc, which is based in Parsippany, New Jersey.

The dispute arose after Sankyo said it would no longer uphold contractual obligations relating to the sales, marketing and distribution of Biographer, Cygnus had alleged.

Sankyo will book an extraordinary loss of $30 million in the October-December quarter, a company spokesman in Tokyo said on Wednesday.

"We have decided to settle the case as we believe our U.S. unit's priority is to focus on marketing of our hypertension drug Benicar and hyperlipidemia agent WelChol," he said.

In November, Sankyo forecast a group net profit of 34 billion yen ($316.6 million) for the current business year through March 31. The spokesman said the company did not know if it would revise its full-year projection as it would need to take into consideration other factors.

Shares in Sankyo were down 0.99 percent at 2,000 yen in Wednesday afternoon trade on the Tokyo stock market, compared with a 0.24 percent drop in the benchmark Nikkei average (^N225 - News). ($1=107.39 yen)